Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Enliven Therapeutics has closed an upsized public offering generating approximately $460.0 million in gross proceeds, which included the full exercise of the underwriters' option to purchase additional shares. The offering consisted of 10,533,334 shares of common stock priced at $37.50 per share, along with pre-funded warrants to purchase 1,733,333 shares at $37.499 per warrant. Jefferies, Goldman Sachs & Co.
Key figures
- Deal Value Usd
- 460000000
- Offering Price
- 37.5
- Shares Offered
- 10533334
- Pre funded warrant price
- 37.499
- Pre funded warrants offered
- 1733333
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.